Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's Astegolimab?
Astegolimab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Data Insights
Astegolimab by F. Hoffmann-La Roche for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Astegolimab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD)....